닫기
검색

ADC

Chase two hares with ADC (Antibody-Drug Conjugate)

We must admit that cancers are smarter than us. Time is our biggest enemy when fighting against cancers because cancers under attack change themselves or their environments over time to survive. Such changes become the main reason for cancer drug resistance.

We need a blitz attack that could kill cancers before they mutate, hide, or find a way to avoid. From experience, though, we are aware that the attack should be safe and tolerable. Safe blitz attack. Sounds contradictory?

Chase two hares with ADC.

When our antibody designed to fit for ADC meets our proprietary linker technology that enables site-specific conjugation of various payloads to an intact antibody, the contraction becomes a reality. (Yes, we have a platform linker.)

Despite an old controversy, we firmly believe that the antibody is the most critical part of ADC. If not agreeable, ask people around you working in this field. Which part of ADC is the hardest to buy in?